Immunic (IMUX)
(Delayed Data from NSDQ)
$1.79 USD
+0.18 (11.18%)
Updated Sep 18, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Immunic (IMUX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.75 | $28.00 | $5.00 | 612.29% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Immunic comes to $12.75. The forecasts range from a low of $5.00 to a high of $28.00. The average price target represents an increase of 612.29% from the last closing price of $1.79.
Analyst Price Targets (6 )
Broker Rating
Immunic currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 5 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/16/2024 | EF Hutton Financial | Jason Kolbert | Not Available | Strong Buy |
9/9/2024 | SVB Securities | Faisal A Khurshid | Not Available | Strong Buy |
8/27/2024 | B. Riley Securities | William Wood | Strong Buy | Strong Buy |
7/16/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
4/5/2024 | Brookline Capital Markets | Tyler Bussian | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $12.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -0.22 |
IMUX FAQs
Immunic, Inc. (IMUX) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Immunic, Inc. (IMUX) is $12.75. The current on short-term price targets is based on 5 reports.
The forecasts for Immunic, Inc. (IMUX) range from a low of $5 to a high of $28. The average price target represents a increase of $612.29 from the last closing price of $1.79.
The current UPSIDE for Immunic, Inc. (IMUX) is 612.29%
Based on short-term price targets offered by six analysts, the average price target for Immunic comes to $12.75. The forecasts range from a low of $5.00 to a high of $28.00. The average price target represents an increase of 612.29% from the last closing price of $1.79.